Samuel Su Explores the Future of Biotech at Tamkang University
On November 5, 2026, Samuel Su, CEO of Bestat Pharmaservices Corp., was invited to speak at Tamkang University's "VIGI" Smart Management and Digital Transformation Program. Under the theme "Future Frontiers: Strategic Industry Outlook—Biotechnology, Health, and the Longevity Economy," Samuel shared insights into emerging trends in the biopharmaceutical industry, clinical trial practices, AI applications, business management, and market competitiveness. Combining professional expertise with practical business perspectives, his presentation was well received by participants, who expressed that they had gained valuable insights from the session.
"VIGI" is an executive education program developed by Tamkang University specifically for small and medium-sized business owners and senior executives. Featuring a distinguished faculty of Golden Eagle Award recipients, industry experts, and university professors, the program integrates industry trends, real-world experience, and structured learning to help business leaders strengthen their decision-making capabilities and maintain a competitive edge in the era of AI and digital transformation.
During the lecture, Samuel provided an overview of the biopharmaceutical industry, covering pharmaceuticals, medical devices, regenerative medicine, and emerging biotechnology sectors. He explained the drug development journey, from basic research and preclinical studies to human clinical trials and regulatory approval. He emphasized that successful biotechnology innovation requires more than scientific breakthroughs. A sound regulatory framework, rigorous clinical research, and reliable data quality are equally essential to transforming research outcomes into commercially viable medical products.
As AI continues to advance rapidly, the biopharmaceutical industry is entering a new era of transformation. Samuel explored the potential applications of AI in clinical trial design, patient recruitment, data management, and risk monitoring, highlighting how emerging technologies can improve research efficiency and decision-making. He also stressed that technological innovation must remain grounded in scientific validation, research ethics, and regulatory compliance to deliver truly reliable results.
Beyond industry knowledge, Samuel drew upon his entrepreneurial journey and experience leading Bestat to share how companies can strengthen their competitive advantages through brand positioning, talent development, organizational management, and strategic thinking. He noted that while technical expertise forms an essential foundation for business growth, the ability to translate that expertise into value recognized by customers and establish a sustainable business model is equally critical to long-term success.
The lecture also aligned with the United Nations Sustainable Development Goals (SDGs), particularly SDG 4: Quality Education, SDG 9: Industry, Innovation and Infrastructure, and SDG 3: Good Health and Well-being. By sharing practical industry experience and professional knowledge, the session helped strengthen connections between education and industry while highlighting the important role of technological innovation and clinical research in advancing medical progress and improving human health.
From scientific discovery to commercial applications, and from conventional clinical trials to AI-driven innovation, the future of biotechnology presents both exciting opportunities and new challenges. Samuel's presentation not only offered participants a deeper understanding of the biopharmaceutical industry but also highlighted a key consideration for business leaders: True competitiveness lies not merely in adopting new technologies, but in transforming innovation into reliable, actionable, and lasting value.
On November 5, 2026, Samuel Su, CEO of Bestat Pharmaservices Corp., was invited to speak at Tamkang University's "VIGI" Smart Management and Digital Transformation Program. Under the theme "Future Frontiers: Strategic Industry Outlook—Biotechnology, Health, and the Longevity Economy," Samuel shared insights into emerging trends in the biopharmaceutical industry, clinical trial practices, AI applications, business management, and market competitiveness. Combining professional expertise with practical business perspectives, his presentation was well received by participants, who expressed that they had gained valuable insights from the session.
"VIGI" is an executive education program developed by Tamkang University specifically for small and medium-sized business owners and senior executives. Featuring a distinguished faculty of Golden Eagle Award recipients, industry experts, and university professors, the program integrates industry trends, real-world experience, and structured learning to help business leaders strengthen their decision-making capabilities and maintain a competitive edge in the era of AI and digital transformation.
During the lecture, Samuel provided an overview of the biopharmaceutical industry, covering pharmaceuticals, medical devices, regenerative medicine, and emerging biotechnology sectors. He explained the drug development journey, from basic research and preclinical studies to human clinical trials and regulatory approval. He emphasized that successful biotechnology innovation requires more than scientific breakthroughs. A sound regulatory framework, rigorous clinical research, and reliable data quality are equally essential to transforming research outcomes into commercially viable medical products.
As AI continues to advance rapidly, the biopharmaceutical industry is entering a new era of transformation. Samuel explored the potential applications of AI in clinical trial design, patient recruitment, data management, and risk monitoring, highlighting how emerging technologies can improve research efficiency and decision-making. He also stressed that technological innovation must remain grounded in scientific validation, research ethics, and regulatory compliance to deliver truly reliable results.
Beyond industry knowledge, Samuel drew upon his entrepreneurial journey and experience leading Bestat to share how companies can strengthen their competitive advantages through brand positioning, talent development, organizational management, and strategic thinking. He noted that while technical expertise forms an essential foundation for business growth, the ability to translate that expertise into value recognized by customers and establish a sustainable business model is equally critical to long-term success.
The lecture also aligned with the United Nations Sustainable Development Goals (SDGs), particularly SDG 4: Quality Education, SDG 9: Industry, Innovation and Infrastructure, and SDG 3: Good Health and Well-being. By sharing practical industry experience and professional knowledge, the session helped strengthen connections between education and industry while highlighting the important role of technological innovation and clinical research in advancing medical progress and improving human health.
From scientific discovery to commercial applications, and from conventional clinical trials to AI-driven innovation, the future of biotechnology presents both exciting opportunities and new challenges. Samuel's presentation not only offered participants a deeper understanding of the biopharmaceutical industry but also highlighted a key consideration for business leaders: True competitiveness lies not merely in adopting new technologies, but in transforming innovation into reliable, actionable, and lasting value.